SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle (ORCL) is trending after reporting strong earnings that beat estimates and raising its FY27 revenue guidance, driven by explosive cloud infrastructure growth and a massive increase in Remaining Performance Obligations from AI contracts. The community is actively discussing whether these robust results, which highlight significant customer prepayments for AI capacity, will finally overcome prior concerns about the company's capital expenditures.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is actively discussed following an earnings miss and reduced fiscal guidance, fueling a steep sell-off. While some in the community highlight robust demand for drone solutions amid global conflicts and the company's ongoing contract negotiations, others express concern over valuation and acquisition integration.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after reporting its first-ever quarterly profit and providing strong delivery guidance, leading to multiple analyst upgrades and fueling community excitement about a potential short squeeze and a long-awaited rebound for the EV innovator, especially with its advanced in-house chip development.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is trending following its recent positive financial results, which reported increased North America local revenue and billings, fueling a turnaround narrative. Community discussion is sharply divided between those anticipating a short squeeze due to high short interest and its valuable SumUp stake, and skeptics who view the stock as fundamentally overvalued and manipulated.

The Beachbody Co., Inc. operates as a health and wellness company. It offers holistic health and wellness platforms. The company's product offerings include digital subscriptions, nutritional products, and connected fitness products. Digital subscriptions include Beachbody On Demand (BOD) and Openfit. The subscriptions are renewed on a monthly, quarterly, or annual basis and include unlimited access to a library of live and on-demand fitness and nutrition content. Nutritional products include Shakeology, Beachbody Performance supplements, BEACHBARs, and others. Connected fitness products include The Beachbody Bike (also known as Myx), which is equipped with a swivel touch screen that enables users to engage with content beyond the indoor cycling experience and encourages broader cross-training, incorporating resistance training and yoga for a more holistic fitness experience and healthier results. The company was founded by Carl Daikeler and Jon Congdon in 1998 and is headquartered in El Segundo, CA.

Beachbody Company Inc (The) - Ordinary Shares - Class A

BODI is trending as its recent financial results, showing positive adjusted EBITDA and projected positive cash flow, fuel speculation of a turnaround for the fitness company. This has ignited a split in the community, with some anticipating a recovery while long-term investors remain deeply wary of past dilution and management's promises.

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

SIGA Technologies Inc

Investors are buzzing about SIGA Technologies following its recent Q4 earnings, with community discussions centering on the company's robust cash reserves, the likelihood of a special dividend, and the highly anticipated new BARDA contract for TPOXX, solidifying its role in biodefense amidst ongoing global health concerns.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Aldeyra Therapeutics is trending as its March 16 PDUFA date approaches for the dry eye treatment Reproxalap, where community sentiment is sharply divided between hopes for approval following a draft label and a recent procedural extension, and concerns over prior rejections, a quiet review beyond the labeling milestone, and a key executive's departure.

goeasy Ltd. engages in the provision of non-prime leasing and lending services. The company was founded by Gordon J. Reykdal on December 14, 1990 and is headquartered in Mississauga, Canada.

Goeasy Ltd

Goeasy Ltd. is trending due to the unexpected suspension of its dividend and withdrawal of financial guidance, alongside reports of significant loan write-offs. This has fueled community speculation about potential mismanagement, class-action lawsuits, and a broader credit crisis, despite some investors viewing the sharp decline as an oversold opportunity.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is trending following its transformative $615 million acquisition of Covelya Group, immediately scaling the company into a comprehensive subsea robotics platform with expanded global capabilities in defense, offshore energy, and ocean science. The community remains highly bullish despite recent share dilution, focusing on its strategic vertical integration, crucial role in maritime security amid geopolitical tensions, and the potential for a future NASDAQ uplisting to unlock significant institutional investment.

Tidal Trust II - Defiance Daily Target 2X Long ORCL ETF

Defiance Daily Target 2X Long ORCL ETF

ORCX is trending as the community debates Oracle's market reaction to its recent earnings, with active traders either capitalizing on volatility or building positions, fueled by optimism for a strong rebound driven by catalysts such as the TikTok deal and potential debt reduction from partnerships like OpenAI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Drove CASI Pharmaceuticals' 24% Rise After Hours?

CASI Pharmaceuticals shares surged over 24% after hours to $0.28 despite a formal Nasdaq delisting and plans to transition to OTC Markets.read more...

<ul class="summary-bullets"><li>As a result of the delisting decision, CASI’s shares will be suspended for trading at the opening of business on Thursday.</li><li>The company stated that it does not intend to review the Nasdaq’s delisting decision.</li><li>CASI stated in its announcement that it expects the company's existing shares to be traded on the over-the-counter market operated by OTC Markets Group Inc.</li></ul>CASI Pharmaceuticals Inc. (CASI) shares tanked more than 64% in Wednesday’s opening trade after the company announced that it had received a delisting decision from the Nasdaq.CASI stated that the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market.As a result of the delisting decision, CASI’s shares will be suspended for trading at the opening of business on Thursday. The company stated that it does not intend to review the Nasdaq’s delisting decision.CASI had received an extension in December 2025 to comply with the Nasdaq’s Market Value of Listed Securities (MVLS) Rule 5550(b)(2) by Feb. 17, 2026.The MVLS rule requires a company’s market capitalization to be above $35 million for 30 consecutive trading days.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CASI">CASI Pharmaceuticals</a> trended in the ‘bullish’ territory.<h2 class="st-heading-2">Where Will CASI’s Existing Shares Be Traded Now?</h2>CASI stated in its announcement that it expects the company's existing shares to be traded on the over-the-counter market operated by OTC Markets Group Inc.However, the company said there is no guarantee that this will materialize.“The delisting from Nasdaq will have no significant impact on the Company's operations,” the company said.<h2 class="st-heading-2">What Does CASI Do?</h2>CASI is a San Francisco, California-based biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for the treatment of organ transplant rejection and autoimmune diseases.In January, CASI announced additional data from its Phase 1 open-label study of CID-103 in adult patients with immune thrombocytopenia (ITP). The company stated that CID-103 demonstrated a manageable safety profile, with only two Grade 3 treatment-related events and no dose-limiting toxicities.Grade 3 treatment-related events are severe and medically significant, but not life-threatening adverse events.<a href="https://stocktwits.com/symbol/CASI">CASI stock</a> is down 66% year-to-date and 87% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rxrx-stock-soars-pre-market-on-q4-beat-recursion-reached-inflection-point/cZRy27nR46D">RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low?

CASI stated the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market.

Equity

Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year?

Here is how Alkermes (ALKS) and CASI Pharmaceuticals Inc. (CASI) have performed compared to their sector so far this year.

Are Medical Stocks Lagging  Alkermes (ALKS) This Year?

Veeva Systems (VEEV) Surpasses Q2 Earnings and Revenue Estimates

Veeva (VEEV) delivered earnings and revenue surprises of +4.74% and +2.80%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

VAXART (VXRT) delivered earnings and revenue surprises of +22.22% and +1,206.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.85% and -79.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates

Bioventus (BVS) delivered earnings and revenue surprises of -4.55% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Careside, Inc. develops and sells a proprietary blood testing systems. The Careside system consists of the Careside Analyzer and disposable test cartridges, the H-2000 and Careside connect. The Careside Analyzer is easy to use and can be operated by a non-technical person with appropriate training in connection with use of the device. Its software will enable the user to capture all data required to comply with the clinical laboratory improvement. The company was founded in July 1996 and is headquartered in Culver City, CA.

Careside Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $ORCL earnings Tuesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.36	--	--	N/A
Q3 '25	-$0.40	-$0.40	--	EXPECTED
Q2 '25	-$0.47	-$0.86	-82.98%	MISSED
Q1 '25	-$0.69	--	--	N/A
Q3 '24	-$0.62	-$0.55	11.29%	BEAT

CASI
CASI Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest CASI News

CASICASI Pharmaceuticals Inc